Short answer
Atrium Therapeutics, Inc. (RNA) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M with net income of −$17M.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- Net income
- −$17M
- Operating margin
- -88.0%
- EPS (diluted)
- −$0.97
Source: XBRL data from the Atrium Therapeutics, Inc. (RNA) Q1 2026 10-Q on SEC EDGAR. USD.
Atrium Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized data risk: preliminary or topline results may materially change after additional data, audits, or verification
- Standalone-company risk: post-Separation vendor charges and corporate costs may exceed historical Avidity allocations
- Regulatory risk: all programs remain preclinical, with no prior IND, pivotal-trial, or BLA submission experience
- Operational risk: reliance on third parties for preclinical studies, future trials, and product manufacturing
- Liquidity risk: $267.8 million cash and equivalents expected to fund operations at least 12 months from filing date
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atrium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.